Clinical Oncology: Case ReportsJournal of Oncology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Severe photosensitivity resulting from an interaction between encorafenib and nirmatrelvir/ritonavir in a patient with advanced melanoma: A Case Report

Nirmatrelvir/ritonavir (PAXLOVIDTM, Pfizer) is considered the first line treatment for mild to moderate COVID-19 infection. Ritonavir, a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme, is susceptible to considerable drug-drug interactions with drugs that are metabolized by the CYP3A4 enzyme. Here, we report a case of severe photosensitivity in a patient taking encorafenib for metastatic melanoma after initiating nirmatrelvir/ritonavir treatment for COVID-19 infection. This case serves as a reminder that caution is required by physicians when prescribing nirmatrelvir/ritonavir to patients taking encorafenib or other molecular-targeted BRAF inhibitors for the treatment of V600 BRAF-mutant cancer.

Special Features

Full Text


Track Your Manuscript

Media Partners